No abstract available
MeSH terms
-
Aged, 80 and over
-
Antibodies, Monoclonal, Humanized / adverse effects*
-
Autoantibodies / blood
-
Autoantibodies / immunology
-
Autoantigens / immunology
-
Facial Neoplasms / drug therapy
-
Facial Neoplasms / immunology
-
Facial Neoplasms / pathology
-
Humans
-
Immune Checkpoint Inhibitors / adverse effects*
-
Lupus Erythematosus, Cutaneous / chemically induced
-
Lupus Erythematosus, Cutaneous / diagnosis*
-
Lupus Erythematosus, Cutaneous / drug therapy
-
Lupus Erythematosus, Cutaneous / immunology
-
Male
-
Melanocytes / drug effects*
-
Melanocytes / immunology
-
Melanocytes / pathology
-
Melanoma / drug therapy
-
Melanoma / immunology
-
Melanoma / secondary
-
Prednisolone / therapeutic use
-
Programmed Cell Death 1 Receptor / antagonists & inhibitors
-
Programmed Cell Death 1 Receptor / immunology
-
RNA, Small Cytoplasmic / immunology
-
Ribonucleoproteins / immunology
-
Skin / drug effects
-
Skin / immunology
-
Skin / pathology
-
Skin Neoplasms / drug therapy
-
Skin Neoplasms / immunology
-
Skin Neoplasms / pathology
Substances
-
Antibodies, Monoclonal, Humanized
-
Autoantibodies
-
Autoantigens
-
Immune Checkpoint Inhibitors
-
PDCD1 protein, human
-
Programmed Cell Death 1 Receptor
-
RNA, Small Cytoplasmic
-
RO60 protein, human
-
Ribonucleoproteins
-
Prednisolone
-
pembrolizumab